The small-molecule injectable market is estimated to capture a valuation of USD 65.10 billion in 2023 and is projected to reach USD 131.70 billion by 2033. The market is estimated to secure a CAGR of 7.3% during the forecast period.
The Rising Prevalence of Chronic Diseases Drives the Global Market.
Several key factors are contributing a significant role to driving the global market are:
Rising Chronic Diseases: The rising cardiovascular diseases, cancer, diabetes, and liver infection are increasing the demand for small-molecule injectables. These drugs are broad uses to manage diseases, targeted therapies, and symptom relief.
Technological Advancements: Growing technologies in advanced drug therapies and delivery systems fuel the global market. Innovation of nanotechnology, self-administration devices, and sustained-release systems expanding the global market.
Growing Aging Population: The global population is rapidly growing, increasing the incidence of chronic diseases. The small-molecular injectables prevent neurodegenerative disorders, arthritis, and osteoporosis among the elder are significantly drive the global market.
Expansion of Biologics Market: The biologics market is rapidly growing the demand for small molecule injectables. These biological drugs are relatively high costs and complex manufacturing processes. However, small-molecular injectable drugs are cost-effective compared to those driving the global market.
Rising Healthcare Expenditure: The growing economies, improving technologies, growing healthcare expenditures, and awareness positively impact the global market. Healthcare provides advanced therapies such as small-molecule injectables.
Emerging Markets: The growing economies in Asia Pacific are improving the healthcare infrastructure, rising economies, and expanding the healthcare infrastructure. These emerging markets are contributing a key role in driving the global market.
| Attribute | Details |
|---|---|
| Market CAGR (2023 to 2033) | 7.3% |
| Market Valuation (2023) | USD 65.10 billion |
| Market Valuation (2033) | USD 131.70 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Small-molecule injectables require complex equipment for manufacturing, each of which needs proper certification and sterilization before production.
It also leads to high operating costs and debt levels due to purchasing and renting capital equipment. In addition, the regulatory cost burden is high due to FDA mandates for maintaining the quality of products while manufacturing, packaging, storage, and distribution.
Monopoly in manufacturing and sourcing small-molecule injectables is also causing disruptions in the supply chain. It might hamper the availability of drugs, resulting in dampened sales prospects for small-molecule injectables.
As per Future Market Insights (FMI), the global market grew at a steady CAGR of 7.3% between 2018 and 2022. The market captured a valuation of USD 45.77 billion in 2018 and USD 60.67 billion in 2022.
The growing prevalence of chronic diseases and fast-track approvals of new drugs for treatment are expected to drive sales of small-molecule injectables.
Leading pharmaceutical companies aim to expand production facilities through mergers, acquisitions, and collaborations to improve their product portfolios. For Instance, In April 2021, Dr. Reddy's Laboratories announced the launch of a generic version of Sapropterin Dihydrochloride powder for oral solution, 100 mg, in the USA Market.
In July 2020, the United States FDA cGMP inspection was completed at Cipla's API manufacturing facility in Virgonagar, Bengaluru. These developments are expected to bode well for the global small-molecule injectables market.
As per Future Market Insights (FMI), the global market recorded a steady CAGR of 7.3% between 2018 and 2022. Moreover, the market captured a valuation of USD 45.77 billion in 2018 and USD 60.67 billion in 2022.
Principal Consultant
By product, the analgesics segment is anticipated to hold the maximum share of 23.9% in 2023, expanding at 8.0% CAGR during the forecast period. Revenues from analgesics are expected to grow, primarily due to the increase in accidents, surgeries, and hospitalizations. Analgesics help manage pain, relieve anxiety, improve healing, and accelerate recovery.
In terms of application, the infectious disease segment is projected to account for 31.7% of the total market share in 2023. Increasing adoption of small-molecule injectable drugs in infectious disease control and treatment is expected to continue spurring demand for small-molecule injectables during the forecast period.
By route of administration, the intravenous segment is projected to account for 49.8% of the total market share in 2023.
The intravenous route is considered the significant route of drug administration, and injectables are directly introduced into the bloodstream. Considering this, sales of small-molecule injectables in the intravenous route of administration segment are expected to remain high over the forecast period.
By distribution channel, hospital pharmacies are anticipated to account for 67.8% of the total small-molecule injectable market share in 2023. Increasing hospitalizations and the availability of skilled professionals to inject drugs are estimated to fuel the segment's growth.
The United States is estimated to account for over 92.4 % of the North American small-molecule injectable market in 2023. Demand for small-molecule injectables is increasing in the United States due to the increasing incidence of chronic diseases among the geriatric population and growing hospitalization rates and surgeries.
Germany is expected to account for 21.9% of Europe's small-molecule injectable market by 2033. Growing demand for small-molecule injectables in Germany is attributable to the rapid expansion of healthcare infrastructure, the presence of prominent players, and the rapid adoption of technologically advanced equipment and processes in the healthcare sector.
Sales of small-molecule injectables in China are projected to record a 9.0% CAGR in East Asia throughout the forecast period.
Increasing use of oncology-related medicines in hospitals to treat various types of cancer, rising demand for analgesics for surgical pain management, and wide availability of biopharmaceutical raw materials are expected to continue pushing sales of small-molecule injectables in China.
Demand for small-molecule injectables in India is expected to rise at an impressive 11.1% CAGR over the forecast period. Growing healthcare awareness, surging demand for advanced medical technologies, an increase in hospitalizations, and streamlined raw material procurement are expected to expand the small-molecule injectable market in India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Manufacturers expand the global market through various strategies and approaches as follows:
Research and Development: Key players invest considerable amounts in research and development activities to develop better small-molecule injectables. These manufacturers optimize drug formulations, improve efficiency, identify novel therapeutic targets, and enhance delivery systems. Through research and development, the manufacturers innovate drug therapies with advanced technologies.
Therapeutic Diversification: Manufacturers expand the global market by expanding therapeutic areas. They identify medical needs, develop injectable formulations for new patients, and expand the therapeutic portfolio.
Formulation Innovation: Manufacturers are innovating and enhancing the small molecule injectables' properties by developing depot formulations and sustained-release formulations. It helps to improve patients and enhance efficiency.
Education and Awareness: Manufacturers invest in educating their patients, healthcare providers, and caregivers to increase the awareness of small molecule injectables. These drugs enhance safety and efficiency during treatment. Manufacturers highlight these drugs' benefits in their conferences, publications, and patient awareness programs.
Geographical Expansion: Manufacturers identify locations to setting up their markets with potential growth. They analyze, research, and identify requirements and healthcare infrastructure in regions to expand the global market. They setups distribution networks and adopt marketing strategies to boost the global market.
Companies operating in the small molecule Injectable invest in strategic collaborations, mergers, and acquisitions to improve their product portfolios. Drug approvals and production facility expansions remain part of market players' growth strategies to gain a competitive edge.
Key players contribute to expanding the global market by innovating new products with these strategies. They are focusing on consumers' desires and developing products accordingly.
These are vital companies fueling the global market during the forecast period with their innovations and the development of new small molecular drugs and therapies.
Other Prominent Players in the Global Market are:
Recent Developments in the Global Market are:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD billion for Value |
| Key Countries Covered | The United States, The United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Product Type, Application Type, Distribution Channel, Route of Administration, Region |
| Key Companies Profiled | Aurobindo Pharma Limited; Teva Pharmaceutical Industries Ltd.; Merck & Co. Inc.; AstraZeneca Plc; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Novartis AG; Baxter International; Fresenius Kabi; Cipla Ltd; Mylan N.V.; Sanofi S.A; Dr. Reddy’s Laboratories Ltd. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The growth potential of this market is 7.3% through 2033.
Germany is expected to acquire 21.9% of the market shares by 2033.
The intravenous segment holds 49.8% of the total market share.
Merck & Co. Inc., AstraZeneca Plc, and Pfizer Inc. are the key market players.
Growth in technological advancements drives sales.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Small Molecule Antibiotics 5.2. Chemotherapy Agents 5.3. Local and General Anaesthetics 5.4. Skeletal Muscle Relaxants 5.5. Analgesics 5.6. Anticoagulants 5.7. Anticonvulsants 5.8. Antivirals 5.9. Anti-histamines/ Anti-allergy 5.10. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Oncology 6.2. Pain Management 6.3. Cardiovascular Diseases 6.4. Infectious Diseases 6.5. CNS Diseases 6.6. Blood Disorders 6.7. Musculoskeletal Disorders 6.8. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Intravenous (IV) 7.2. Intramuscular (IM) 7.3. Subcutaneous (SC) 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. Drug Stores 8.4. Mail Order Pharmacies 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. MEA 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Aurobindo Pharma Limited 19.2. Teva Pharmaceutical Industries Ltd. 19.3. Merck & Co. Inc. 19.4. AstraZeneca Plc 19.5. Pfizer Inc. 19.6. Sun Pharmaceutical Industries Ltd. 19.7. Novartis AG 19.8. Baxter International 19.9. Fresenius Kabi 19.10. Cipla Ltd 19.11. Mylan N.V. 19.12. Sanofi S.A 19.13. Dr. Reddy’s Laboratories Ltd. 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Small-Molecule Injectable Market
